Isolated intestinal versus composite visceral allografts: causes of graft failure.
de Vera
M E
ME
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.
Reyes
J
J
Demetris
J
J
Mazariegos
G
G
Schaefer
N
N
Vargas
H
H
Bond
G
G
Wu
T
T
Fung
J
J
Starzl
T E
TE
Abu-Elmagd
K
K
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D007422:Intestines / Q000637:transplantation*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000453:epidemiology; D011183:Postoperative Complications / Q000145:classification* / Q000453:epidemiology; D012189:Retrospective Studies; D013997:Time Factors; D014184:Transplantation, Homologous / Q000276:immunology / Q000379:methods*; D017211:Treatment Failure; D014781:Viscera / Q000637:transplantation*
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D009173:Mycophenolic Acid; D001379:Azathioprine